Previous Article | Next Article ![]()
Infection and Immunity, August 2004, p. 4603-4611, Vol. 72, No. 8
0019-9567/04/$08.00+0 DOI: 10.1128/IAI.72.8.4603-4611.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Hechmi Louzir,1,
Chahnaz Kebaïer,1 Samir Boubaker,1 Koussay Dellagi,1 and Pierre-André Cazenave2*
Laboratory of Immunology (LAF 301), Institut Pasteur de Tunis (WHO Collaborating Center for Training and Research on Leishmaniasis), 1002 Tunis-Belvédère, Tunisia,1 Unité d'Immunophysiopathologie Infectieuse, CNRS URA 1961 and Université Pierre et Marie Curie, Institut Pasteur, 75724 Paris Cedex 15, France2
Received 11 July 2003/ Returned for modification 6 November 2003/ Accepted 3 May 2004
Two inbred mouse strains, derived from feral founders, are susceptible to experimental leishmaniasis due to Leishmania major and support a disease of a severity intermediate between those observed in strains C57BL/6 and BALB/c. Mice of the MAI strain develop a severe, nonhealing, but nonfatal disease with no resistance to a secondary parasite challenge. The immunological responses showed a TH2 dominance characterized by an early peak of interleukin-4 (IL-4) and IL-13. However, neutralization of IL-4, which leads to a resistance phenotype in BALB/c mice, has no effect on disease progression in MAI mice. Mice of strain PWK develop a protracted but self-healing disease, characterized by a mixed TH1-plus-TH2 pattern of immune responses in which IL-10 plays an aggravating role, and acquire resistance to a secondary challenge. These features are close to those observed in human cutaneous leishmaniasis due to L. major and make PWK mice a suitable model for the human disease.
B.E.C.B. and H.L. contributed equally to this study.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|